FOI release

Freedom of Information request on the COVID-19 vaccines and PCR testing (FOI 21/1017)

Published 27 April 2022

18th October 2021

FOI 21/1017

Dear

Thank you for your email.

With regards to your questions please find our answers below.

1) Why are we vaccinating people who have had covid and therefore have a natural immunity to the virus ? This is not under the remit of MHRA and as such we would advise you contact JCVI.

2) Why did you insist on the pcr test being used when you know the Dr who invented it went on record saying it can’t be used to detect a virus ? The use of CE/UKCA marked PCR tests does not require MHRA approvals.

Different PCR tests will have different performance claims which is clearly stated in the tests Instruction For Use (IFU). You may be interested to know that Public Health England (PHE) had undertaken rapid assessments of commercially provided diagnostic tests for SARS-CoV-2 nucleic acid detection. You can access their reports at https://www.gov.uk/government/publications/covid-19-phe-laboratory-assessments-of-molecular-tests.

We suggest that you consult the Scientific Advisory Group for Emergencies (SAGE) website (https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies), which includes information supporting the governments’ decision making on the Covid-19 pandemic.

3) Why are we still testing people for covid but not testing for natural immunity ? As Israel has proved natural immunity is far far better than any vaccines This is not under the remit of MHRA and as such we would advise you contact the Department of Health and Social Care.

4) Why are people who die within two weeks of vaccination being recorded as unvaccinated when we know it was the vaccine that killed them. This is not under the remit of MHRA and as such we would advise you contact your local health authority.

5) Can you provide me with the following details

• Number of reported blood clots in 2020

• Number or reported blood clots in 2021

• Number of heart attacks in 2020

• Number of heart attacks in 2021

• Number of strokes in 2020

• Number of strokes in 2021

This is not under the remit of MHRA, we only collect information regarding adverse reactions to medicines and medical devices. As such we would advise you contact your local health authority.

6) How much funding you received in the following years from pharmaceutical companies

• 2017

• 2018

• 2019

• 2020

• 2021

And which pharmaceutical companies funded you by what amounts?

MHRA does not and has never received any funding from pharmaceutical companies.

The Yellow Card scheme is run by the MHRA and is the UK system for collecting and monitoring information on safety concerns such as suspected side effects or adverse incidents involving medicines and medical devices. Reports received through our Yellow Card scheme associated with the COVID-19 vaccines including reports associated with a fatal outcome can be viewed by following the link below: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions.

When viewing the data at the link above you should remember that:

• Reporters are asked to submit Yellow Card reports even if they only have a suspicion that the medicine or vaccine may have caused the adverse reaction. The existence of an adverse reaction report in the profile does not necessarily mean that the vaccine has caused the suspected reaction.

• It may be difficult to tell the difference between something that has occurred naturally and a suspected adverse reaction. Sometimes these events can be part of the condition being treated rather than being caused by the vaccine.

• Many factors have to be considered when assessing whether the vaccine has caused a reported adverse reaction. When monitoring the safety of vaccines and medicines, MHRA staff carry out careful analysis of these factors.

As with any vaccine or medicine, COVID-19 vaccines require continuous safety monitoring and that the benefits in protecting people against COVID-19 outweigh any side effects or potential risks. This is a process known as safety monitoring (pharmacovigilance). This ensures that any potential medium and long term safety issues are promptly and adequately evaluated. As part of our signal detection processes, all adverse reaction reports received are individually assessed and cumulative information reviewed at regular intervals. Be reassured that the MHRA is working in collaboration with partners in the health system to rapidly assess all available safety data in real time and communicate any emerging issues, as necessary.

Vaccination is the single most effective way to reduce deaths and severe illness from COVID-19. Following widespread use of these vaccines across the UK, the vast majority of suspected adverse reaction reports so far confirm the safety profile seen in clinical trials. Most reports relate to injection-site reactions (sore arm for example) and generalised symptoms such as a ‘flu-like’ illness, headache, chills, fatigue, nausea, fever, dizziness, weakness, aching muscles, and rapid heartbeat. Generally, these reactions are not associated with more serious illness and likely reflect an expected, normal immune response to the vaccines.

Vaccination and surveillance of large populations means that, by chance, some people will experience and report a new illness or events in the days and weeks after vaccination. A high proportion of people vaccinated early in the vaccination campaign were very elderly, and/or had pre-existing medical conditions. Older age and chronic underlying illnesses make it more likely that coincidental adverse events will occur, especially given the millions of people vaccinated. It is therefore important that we carefully review these reports to distinguish possible side effects from illness that would have occurred irrespective of vaccination. Part of our continuous analysis includes an evaluation of natural death rates over time, to determine if any specific trends or patterns are occurring that might indicate a vaccine safety concern. Based on age-stratified all-cause mortality in England and Wales taken from the Office for National Statistics death registrations, several thousand deaths are expected to have occurred, naturally, within 7 days of the many millions of doses of vaccines administered so far, mostly in the elderly.

Usage of the vaccines has increased over the course of the campaigns and as such, so has reporting of fatal events with a temporal association with vaccination however, this does not indicate a link between vaccination and the fatalities reported. Review of individual reports and patterns of reporting does not suggest the vaccines played a role in these deaths.

The expected benefits of the vaccines in preventing COVID-19 and serious complications associated with COVID-19 far outweigh any currently known side effects. As with all vaccines and medicines, the safety of COVID-19 vaccines is continuously monitored and benefits and possible risks remain under review.

With reference to your query surrounding information provided at vaccine centres, this not under the remit of MHRA and as such we would advise you contact your local health authority.

If you have a query about the information provided, please reply to this email

If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask for an internal review. Please reply to this email, within two months of this reply, specifying that you would like an Internal Review to be carried out.

Due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner’s Office

Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely

MHRA Customer Service Centre

Medicines and Healthcare products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU